3.4.21.46: complement factor D
This is an abbreviated version!
For detailed information about complement factor D, go to the full flat file.
Word Map on EC 3.4.21.46
-
3.4.21.46
-
angiogenesis
-
angiogenic
-
vessel
-
metastasis
-
neovascularization
-
hypoxia
-
artery
-
hypoxia-inducible
-
necrosis
-
retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
-
vein
-
capillary
-
factor-1
-
huvecs
-
vegfr-2
-
collagen
-
vasculature
-
retinopathy
-
eyes
-
ovarian
-
macular
-
tumour
-
tube
-
microvascular
-
mesenchymal
-
anti-vegf
-
lymphatic
-
receptor-2
-
pro-angiogenic
-
bfgf
-
intravitreal
-
progression-free
-
edema
-
choroid
-
metalloproteinase
-
endothelium
-
hypertension
-
sprout
-
matrigel
-
paracrine
-
lymph
-
hif-1alpha
-
mmp-9
-
sunitinib
-
drug development
-
sorafenib
-
vitreous
-
medicine
- 3.4.21.46
- angiogenesis
-
angiogenic
- vessel
- metastasis
- neovascularization
- hypoxia
- artery
-
hypoxia-inducible
- necrosis
- retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
- vein
- capillary
- factor-1
- huvecs
- vegfr-2
- collagen
- vasculature
- retinopathy
- eyes
- ovarian
-
macular
- tumour
- tube
-
microvascular
- mesenchymal
-
anti-vegf
- lymphatic
- receptor-2
-
pro-angiogenic
- bfgf
-
intravitreal
-
progression-free
- edema
- choroid
- metalloproteinase
- endothelium
- hypertension
-
sprout
- matrigel
-
paracrine
- lymph
- hif-1alpha
- mmp-9
- sunitinib
- drug development
- sorafenib
- vitreous
- medicine
Reaction
selective cleavage of Arg-/-Lys bond in complement factor B when in complex with complement subcomponent C3b or with cobra venom factor =
Synonyms
28 kDa protein, adipocyte, Adipsin, alternative complement pathway component Factor D, C3 convertase activator, C3 proactivator convertase, CFD, complement factor D/adipsin and kallikrein-like serine protease, convertase, C3 proactivator, Df, Df protein, endogenous vascular elastase, esterase, properdin factor D, factor D, factor D (complement), fD, PDGF-D, platelet-derived growth factor D, PoDAK, vascular endothelial growth factor, vascular endothelial growth factor D, VEGF-D
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 3.4.21.46 - complement factor D
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(1R,2S)-2-([4-[3-(aminomethyl)anilino]quinazolin-2-yl]amino)cyclohexane-1-carboxylic acid
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(2-fluoro-3-trifluoromethoxyphenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(2-fluoro-3-trifluoromethylphenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-chlorophenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-difluoromethoxyphenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-methoxyphenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxyphenyl)-amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 3-[(3-bromophenyl)amide] 2-[(1-carbamoyl-1H-indol-3-yl)amide]
-
(1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 3-[(6-bromo-pyridin-2-yl)-amide] 2-[(1-carbamoyl-1H-indol-3-yl)-amide]
-
(1R,3S,5R)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(6-trifluoromethyl-pyridin-2-yl)-amide]
-
(1S,2S,5R)-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 3-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(2S)-2-([4-[3-(aminomethyl)anilino]pyrimidin-2-yl]amino)-3-methylbutanoic acid
-
(2S)-2-([4-[3-(aminomethyl)anilino]quinazolin-2-yl]amino)-3-methylbutanoic acid
-
(2S)-N2-(diphenylmethyl)-N1-(1-methyl-1H-indol-3-yl)pyrrolidine-1,2-dicarboxamide
-
(2S,4R)-4-fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]
-
(2S,4R)-4-methyl-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(2S,4S)-4-amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(2S,4S)-4-fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(2S,4S)-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(2S,4S)-4-methyl-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide
-
(R)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(S)-4,4-difluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(S)-piperidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
(S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxyphenyl)-amide]
-
1-(2-((1R,3S,5R)-3-((6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide
-
1-(2-[(1R,3S,5R)-3-[(6-bromopyridin-2-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl)-1H-indazole-3-carboxamide
-
1-[2-[(1R,3S,5R)-3-[[(1R)-1-(3-chloro-2-fluorophenyl)ethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-1H-indazole-3-carboxamide
-
1-[2-[(1R,3S,5R)-3-[[(1R)-1-(3-chloro-2-fluorophenyl)ethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
-
3'-(aminomethyl)-5-(3-methylbutanamido)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)[1,1'-biphenyl]-3-carboxamide (incorrect configuration definition!)
-
3'-(aminomethyl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl][1,1'-biphenyl]-3-carboxamide
-
3-([3-[3-(aminomethyl)anilino]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino)phenol
-
methyl 2-([[(2S)-2-[[3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidine-1-carbonyl]amino]methyl)benzoate
[2-([3'-[(1S)-1-amino-2-hydroxyethyl][1,1'-biphenyl]-3-yl]methoxy)phenyl]acetic acid
selective inhibitor
-
3'-(aminomethyl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl][1,1'-biphenyl]-3-carboxamide
-
-
an Escherichia coli-expressed, humanized Fab fragment, derived from monoclonal antibody 166-32, and designed as specific enzyme inhibitor targeting the exosite. Anti-factor D Fab fragment prevents factor D-mediated proteolytic activation of its macromolecular substrate C3bB, but not proteolysis of a small synthetic substrate, indicating that the inhibitor does not block access of the substrate to the catalytic site, binding structure and inhibitory mechanism, overview. The structures show that the AFD-binding site includes surface loops of the enzyme that form part of the enzyme's exosite. Anti-factor D Fab fragment inhibits the enzyme proteolytic function by interfering with macromolecular substrate access rather than by inhibiting the enzyme catalysis
-
anti-factor D Fab fragment
-
an Escherichia coli-expressed, humanized Fab fragment, derived from monoclonal antibody 166-32, and designed as specific enzyme inhibitor targeting the exosite. Anti-factor D Fab fragment prevents factor D-mediated proteolytic activation of its macromolecular substrate C3bB, but not proteolysis of a small synthetic substrate, indicating that the inhibitor does not block access of the substrate to the catalytic site, binding structure and inhibitory mechanism, overview. The structures show that the AFD-binding site includes surface loops of the enzyme that form part of the enzyme's exosite. Anti-factor D Fab fragment inhibits the enzyme proteolytic function by interfering with macromolecular substrate access rather than by inhibiting the enzyme catalysis
-
methyl 2-([[(2S)-2-[[3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidine-1-carbonyl]amino]methyl)benzoate
-
methyl 2-([[(2S)-2-[[3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidine-1-carbonyl]amino]methyl)benzoate
-
-
human factor D is a self-inhibited thrombin-like serine proteinase. Ser199 of the self-inhibitory loop blocks the formation of the canonical active configurations
-
additional information
-
human factor D is a self-inhibited thrombin-like serine proteinase. Ser199 of the self-inhibitory loop blocks the formation of the canonical active configurations
-